• Safe Pro Group recently began the commercial rollout of NODE-X, a next-gen miniaturized AI-powered edge compute processor of drone footage for threat detection.
• The rollout began at a U.S. Army Exercise, and NODE-X is scheduled to be a part of additional U.S. Army exercises throughout the second quarter of 2026.
• NODE-X is powered by Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”), a powerful technology used to rapidly analyze drone imagery and video to identify and detect small explosive threats.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-enabled security, defense, and situational awareness solutions, recently started the commercial rollout of NODE-X at a U.S. Army exercise (https://ibn.fm/5IdSl).

Node-X is a next-gen miniaturized AI-powered edge compute processor of drone footage for detecting threats in military support missions. This solution is the next generation of Safe Pro’s AI-powered ecosystem of tools that enable the rapid processing of drone images and videos for AI threat detection, 3D mapping, and route guidance.

The Node-X is designed as a backpack-sized kit that includes real-time AI inference on an edge compute server, as well as rugged GPU laptops running Safe Pro’s OnSight application, which is compatible with U.S. Army-approved short-range recon (“SRR”) drones.

Node-X is powered by Safe Pro’s Safe Pro Object Threat Detection (“SPOTD”), which is a platform that rapidly analyzes videos and images from virtually any drone to detect and classify explosive threats and other small objects of interest. 

The platform converts raw video into high-resolution 2D/3D models that can quickly be shared to support operational decision-making and provide better situational awareness.

Node-X uses AI and machine learning algorithms that are trained on one of the world’s largest imagery datasets from Ukraine, which includes 2.6 million drone images and 47,000 confirmed detections of small threats like landmines, cluster munitions, ambush drones, and unexploded ordnance (“UXO”).

It operates on the edge without any need for connectivity and incorporates AI-detected threats with the fast generation of 3D models and digital surface models, such as terrain slope, vegetation height, and more.

The field-deployable design and intuitive interface of the solution provides both soldiers and military commanders with important situational awareness, which makes it an ideal piece of tech for a variety of different missions.

The Node-X is scheduled to take part in additional U.S. Army exercises through the second quarter of 2026, as Safe Pro builds momentum towards rapid expansion.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and delivers advanced AI-powered security and defense solutions to customers in the law enforcement, defense, homeland security, and humanitarian industries. At the core of Safe Pro’s mission is a patented computer vision software technology used to rapidly and accurately detect small threats and objects in drone photos and videos, to boost the safety of field operations for ground teams.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Integrated geochemical and geophysical data point to structurally controlled mineralization at Atikokan rare earth property.
• Dashwa Gneiss Complex emerges as the primary focus for follow-up work.
• Soil, rock, and sediment sampling indicate consistent rare earth element (“REE”) anomalies.
• Results support a coherent exploration model rather than isolated occurrences.
• The project aligns with rising strategic demand for domestic REE supply in North America.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company focused on rare earth projects across North America, has refined its exploration strategy at the Atikokan Rare Earth Property in northwestern Ontario, identifying priority target zones following a comprehensive integration of geochemical assays and geophysical data. The findings mark a shift from early-stage sampling toward more targeted exploration planning (https://ibn.fm/hbas0).

The company’s latest interpretation combines results from rock, soil, and sediment sampling with airborne magnetic and radiometric surveys conducted in 2025. This dataset has enabled Powermax to delineate zones where rare earth element (“REE”) mineralization may be structurally concentrated, rather than dispersed.

Two distinct geological environments have been identified across the property. The Dashwa Gneiss Complex, covering Blocks B and C, has been prioritized for follow-up exploration. In contrast, the White Otter Batholith, designated as Block A, has been assigned lower priority due to weaker geochemical correlations and more diffuse mineralization patterns.

Sampling results provide the basis for this distinction. Rock samples returned total rare earth oxide (“TREO”) values ranging from 19.1 to 503.3 parts per million, with several readings exceeding 200 ppm. Soil samples showed values up to 615.8 ppm, while sediment samples indicated downstream dispersion of REE-bearing material. These figures fall within ranges typically associated with early-stage exploration systems but show consistent anomaly clustering.

More significant for exploration planning is the spatial relationship of these anomalies. Elevated REE values appear linked to structural corridors, shear zones, and lithological contacts: features that can act as conduits for mineralizing processes. This pattern supports a structurally controlled model, where mineralization is concentrated along deformation zones rather than evenly distributed.

The company’s interpretation also highlights geochemical associations between REEs, thorium, and uranium. Such correlations are commonly used as vectors in rare earth exploration, helping geologists trace surface anomalies back to potential subsurface concentrations. In this case, the presence of minerals such as monazite and allanite, both known hosts for light rare earth elements, reinforces the working model.

The technical work underpinning these findings is extensive. The 2025 program included airborne surveys flown at 50-metre line spacing, along with ground-based mapping, prospecting, and systematic sampling. A total of 426 samples were collected and analyzed by AGAT Laboratories Ltd. using sodium peroxide fusion and ICP-OES/MS methods, providing near-total digestion for REE analysis. Quality control procedures included duplicates, blanks, and standards to ensure data reliability.

Powermax’s approach reflects a broader trend in early-stage mineral exploration, where integrated datasets are used to reduce geological uncertainty before advancing to more capital-intensive drilling campaigns. By combining multiple data types, companies aim to increase the probability of targeting zones with meaningful mineralization.

The strategic context for rare earth elements adds another layer of relevance. Global demand for REEs, critical components in electric vehicles, wind turbines, and advanced electronics, is projected to rise significantly over the next decade. At the same time, supply chains remain heavily concentrated, with China controlling a substantial share of both mining and processing capacity.

This imbalance has prompted policy responses in North America and Europe, including funding initiatives and incentives aimed at developing domestic supply. In the United States, mechanisms such as the Defense Production Act have been used to direct capital toward critical mineral projects, while Canadian companies may also benefit from cross-border collaboration and funding eligibility.

Within this environment, exploration-stage projects such as Atikokan are being evaluated not only on geological merit but also on their potential role in diversifying supply chains. However, it is important to note that the project remains at an early stage. The current results define exploration targets rather than confirmed economic mineralization.

Powermax holds a portfolio of REE-focused properties across Canada and the United States, including projects in British Columbia and Wyoming. The Atikokan property, comprising 455 unpatented mining claims, represents one of its more advanced exploration efforts in terms of integrated data analysis.

The next phase of work is to focus on refining these targets through additional field studies and, potentially, initial drilling campaigns. Such steps will be necessary to determine whether the identified anomalies translate into continuous mineralized zones with economic potential.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• At the core of Cardio Diagnostics’ approach is the use of artificial intelligence to integrate multi-omic data to provide a more comprehensive view of cardiovascular health.
• The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk.
• CDIO’s focus on accessibility and scalability is also notable.

Cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. Cardio Diagnostics Holdings (NASDAQ: CDIO) is at the forefront of this shift, developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample.

At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional diagnostic tools often rely on population-based risk factors such as cholesterol levels, blood pressure and family history. While these indicators are valuable, they may not fully capture individualized disease risk or early molecular changes of disease that precede clinical symptoms. By contrast, epigenetic biomarkers reflect how environmental and lifestyle factors influence gene expression, offering a dynamic layer of insight that evolves over time.

The scientific foundation for this approach is well supported. Research published by the National Institutes of Health highlights that DNA methylation patterns can serve as sensitive indicators of disease risk and biological aging, with applications in cardiovascular conditions. These epigenetic modifications can reveal early disruptions in biological pathways long before structural changes or symptoms may appear, making them particularly valuable for preventive care and early intervention.

Cardio Diagnostics’ platform builds on this concept by combining epigenetic and genetic data with AI algorithms designed to detect complex patterns across large datasets. AI has increasingly been recognized as a powerful tool in healthcare for identifying relationships that may not be apparent through conventional statistical methods. A report from National Academy of Medicine notes that AI can enhance clinical decision-making by uncovering subtle correlations in biomedical data and improving risk prediction models. By applying machine learning to multi-omic inputs, Cardio Diagnostics aims to deliver more accurate and individualized assessments than traditional models.

The company’s proprietary platform is designed to analyze a patient’s molecular profile from a single blood draw and generate actionable insights related to cardiovascular disease risk. This approach simplifies the diagnostic process while improving precision. The use of a blood-based test is particularly important, as it reduces barriers to testing and enables broader accessibility compared to more invasive or resource-intensive diagnostic procedures.

The integration of multiple biomarker types is also a key differentiator. Genetic markers provide information about inherited set points in key biological pathways, while epigenetic markers capture real-time biological responses to factors such as diet, stress and environmental exposures. Together, these data layers create a more complete picture of cardiovascular health. 

This aligns with broader trends in precision medicine, where combining diverse data sources has been shown to improve predictive accuracy. The National Human Genome Research Institute emphasizes that both genomic and epigenomic research enhance the understanding of complex diseases and support more personalized approaches to care, including tailoring treatment based on individual molecular profiles.

Artificial intelligence serves as the analytical engine that makes this integration possible. Machine learning models can process high-dimensional datasets and continuously improve as more data becomes available. This capability is essential when working with epigenetic information, which can vary widely between individuals and over time. By training algorithms on large datasets, platforms such as the one developed by Cardio Diagnostics can identify patterns associated with disease risk or presence of disease and translate them into clinically relevant insights.

The company’s focus on accessibility and scalability is also notable. Blood-based diagnostics are among the fastest-growing segments in precision medicine, driven by their convenience and potential for early detection. A “Nature Medicine Journal” article reports that liquid biopsy approaches, which analyze biomarkers in blood, are increasingly being used to detect and monitor diseases with high sensitivity and specificity. While much of the early work has focused on oncology, similar principles are now being applied to cardiovascular disease, where early detection can significantly influence outcomes.

Cardio Diagnostics’ platform reflects a broader shift toward proactive health care, where the goal is not only to diagnose disease but to predict and prevent it. By leveraging epigenetic and genetic data, the company aims to move beyond static risk assessments and provide insights that evolve with the patient. This dynamic approach has the potential to support more timely interventions and better-informed clinical decisions.

In addition to its technological foundation, CDIO’s platform is designed to fit within existing health-care workflows. The simplicity of a blood test, combined with AI-driven analysis, allows for integration into routine care settings without requiring extensive new infrastructure. This is particularly important as healthcare systems increasingly seek solutions that can scale efficiently while maintaining high levels of accuracy and reliability.

As precision medicine continues to advance, the integration of multi-omic data and artificial intelligence is expected to play a central role in the future of diagnostics. Cardio Diagnostics Holdings is positioning itself within this emerging landscape by developing a platform that combines scientific rigor with practical usability. By translating complex molecular data into actionable insights, the company is contributing to a new generation of diagnostic tools aimed at improving how cardiovascular risk and disease are assessed and managed.

For more information, visit www.CDIO.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

• Greenland Energy holds rights to up to 70% working interest across three onshore licenses covering more than 2 million acres in East Greenland’s Jameson Land Basin.
• Independent Sproule ERCE engineering estimates indicate recoverable oil upside of 13 billion barrels across the basin, which was extensively evaluated by ARCO decades ago but never drilled.
• The company has contracted Stampede Drilling for Arctic-rated rig services alongside agreements with Halliburton, Desgagnés, and IPT Well Solutions to support its 2026 drilling campaign.

Onshore basins of genuine scale that remain undrilled are increasingly rare. Most of the world’s major hydrocarbon-producing regions have been systematically tested over the past half-century, leaving frontier opportunities concentrated in geographies with challenging logistics, complex permitting, or historically limiting macroeconomic conditions. 

Where such basins remain, they carry a combination of technical risk and optionality that draws a specific type of investor interest. The Jameson Land Basin in East Greenland, a petroleum basin historically evaluated by US Atlantic Richfield Company (“ARCO”) but never drilled, represents one of the most prominent examples of that profile. Greenland Energy (NASDAQ: GLND) is the publicly traded platform now advancing it.

When they do emerge, these types of opportunities tend to represent outsized, binary-style outcomes where success or failure can redefine the value of an entire region.

The Jameson Land Basin Opportunity

The Jameson Land Basin covers more than 2 million acres in East Greenland and has been compared geologically to prolific hydrocarbon systems such as Prudhoe Bay in Alaska and the North Sea.

ARCO, following its discovery of the giant Prudhoe Bay oil field, invested the equivalent of more than $275 million in today’s dollars evaluating Jameson, conducting detailed field mapping, acquiring approximately 1,800 kilometers of 2D seismic data, and constructing the Constable Point Airfield that remains a key piece of regional infrastructure. Despite identifying substantial oil potential, the basin remained undrilled due to corporate strategy shifts and macroeconomic conditions rather than unfavorable technical findings.

Greenland Energy has reprocessed the legacy seismic data with modern technology, identifying more than 50 distinct oil and gas targets with structural and stratigraphic trapping potential. An independent Sproule ERCE engineering report indicates upside of 13 billion barrels of recoverable oil across the basin.

In practical terms, much of the early-stage geological risk has already been addressed, what remains is the execution risk of drilling a basin that has never been tested.

From Legacy Data to Public Market Platform

Greenland Energy was formed through the business combination of Pelican Acquisition Corporation, Greenland Exploration Limited, and March GL Company. The transaction closed March 25, 2026, with shares commencing trading on NASDAQ under the ticker symbol “GLND” the following day at an approximately $215 million implied valuation.

Under the structure, Greenland Energy holds rights to own up to 70% of three onshore licenses covering the entire petroleum basin, with working interest earned through a subsidiary of 80 Mile. ThinkEquity LLC served as financial advisor across the transaction.

The formation of a publicly traded platform provides access to capital markets at a stage where large-scale exploration programs require coordinated funding, technical execution, and long-term planning.

Operational Readiness and Partnerships

On March 27, 2026, Greenland Energy announced a five-year strategic drilling agreement with Stampede Drilling Inc. (TSX: SDI), securing Stampede’s Rig #12,  equipped for Arctic conditions, for upcoming operations in the Jameson Land Basin. Plans under the agreement call for drilling up to two wells.

The drilling contract is complemented by agreements with Halliburton for logistics planning and drilling services, Desgagnés for Arctic shipping of drilling equipment, and IPT Well Solutions as project manager providing additional oversight and technical support.

The Greenland Government has approved the mobilization and sealift landing of heavy equipment including a D9 bulldozer, trucks, excavators, loaders, generators, and housing units, which will support construction of a three-mile access road to the drilling site. A 3,500-meter-capable drilling rig has been secured for the program.

Taken together, these agreements move the project from conceptual to executable, a distinction that often defines the transition from narrative to measurable outcomes in frontier exploration.

Leadership and Capital Markets Perspective

Greenland Energy’s leadership includes Larry G. Swets, Jr. as Executive Chairman and Robert Price as Chief Executive Officer, with directors and executives drawn from the predecessor entities.

On March 26, 2026, the company appointed Joe Moglia, former Chief Executive Officer and Chairman of TD Ameritrade, as Executive Advisor to the Board. Moglia brings decades of capital markets and corporate strategy experience, including current roles as Chairman of Fundamental Global and Capital Wealth Advisors and Executive Advisor to FG Nexus.

His appointment adds a layer of capital markets perspective to a company transitioning from formation to execution.

Why the Timing Matters

Western energy security has become an explicit policy priority in recent years, with governments and capital markets increasingly focused on reducing dependence on geopolitically constrained supply sources. Greenland’s emergence as a strategic frontier aligns with that shift, and the Jameson Land Basin’s combination of scale, existing infrastructure, and regulatory progress positions Greenland Energy as an early mover in a region that has drawn attention but seen limited commercial activity.

“Our work in the Jameson Land Basin represents a rare opportunity to unlock one of the largest undrilled onshore basins in the Arctic through a disciplined, environmentally responsible approach,” said Robert Price, Chief Executive Officer of Greenland Energy.

With field activity progressing, equipment mobilization approved, and drilling partnerships in place, the company is moving toward what would be the first modern well drilled in a basin whose potential has been documented, but never tested, for more than four decades.

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at ibn.fm/GLND

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF)and may include paid advertising.

• Planet Ventures provides shareholders with exposure to private space and aerospace companies through a publicly traded investment vehicle.
• The company employs a diversified portfolio strategy spanning infrastructure, software, energy, robotics, and emerging space applications.
• Its investment approach is positioned to benefit from the continued growth and commercialization of the global space sector.
• Recent activity includes investments in Relativity Space (via MCXGP), Antaris following its $28 million Series A financing, and General Astronautics, a Y Combinator Winter 2026 company.
• The company has also deployed capital into early-stage opportunities such as Mantis Space and GRU Space, reflecting a focus on emerging technologies across the space economy.

Planet Ventures (CSE: PXI) (OTC: PNXPF) is an investment issuer focused on identifying and investing in innovative companies operating within the space and aerospace sectors. The company’s strategy is centered on providing shareholders with exposure to emerging, high-growth opportunities, including private companies that are typically accessible primarily to venture capital and institutional investors.

The company employs a portfolio-driven investment approach, seeking to build a diversified base of investments across multiple segments of the space economy. Its activities are focused on sourcing and participating in opportunities globally, leveraging its network and experience to access and evaluate potential investments aligned with long-term growth trends in the sector.

Planet Ventures aims to create shareholder value through strategic capital allocation into companies developing technologies and services that support the expanding commercial space ecosystem.

The company is headquartered in Vancouver, British Columbia.

Portfolio

Planet Ventures operates as an investment platform, deploying capital into companies across the space and aerospace value chain, including infrastructure, software, energy, robotics, and emerging applications.

The company’s investment thesis is based on the view that many of the most significant opportunities in the space sector remain private and are not directly accessible to public market investors. Through its investment approach, Planet Ventures provides shareholders with indirect exposure to these companies, including through positions that may offer access to private businesses typically only available to venture capital and institutional investors.

Launch & Infrastructure

Planet Ventures has gained exposure to Relativity Space Inc. through an investment in MCXGP Relativity Fund I LLC, a special purpose vehicle that participated in the company’s most recent financing round. Relativity Space is developing reusable launch vehicles, including the Terran R rocket, designed for mid-to-heavy lift missions and low Earth orbit satellite deployment.

The company has also invested in Mantis Space Corp., which is developing orbital energy infrastructure intended to deliver power to satellites and other space-based systems.

Software & Data Platforms

Planet Ventures has made a strategic investment in Antaris Inc., an AI-powered platform designed to support the design, simulation, and operation of satellite constellations. The platform is intended to streamline mission development and enable software-driven approaches to space operations.

Emerging Applications & Robotics

Planet Ventures has invested in Galactic Resource Utilization Space Inc. (“GRU Space”), a company focused on developing habitat infrastructure for use beyond Earth, including concepts related to space tourism.

The company has also invested in General Astronautics, a space robotics company developing autonomous systems designed to operate in microgravity environments to support research and manufacturing activities in space.

Market Opportunity

Planet Ventures operates within the global space economy, which is valued at approximately $626 billion in 2025 and is projected to exceed $1.8 trillion by 2035, according to data from the World Economic Forum. Growth in the sector is being driven by increasing commercialization (with commercial revenues accounting for 78% of the total market, according to the Space Foundation), as well as expanding satellite applications, infrastructure development, and national security initiatives.

The space economy encompasses a wide range of activities that can be broadly divided into upstream and downstream segments. Upstream activities include launch systems, satellite manufacturing, and on-orbit operations, while downstream activities include satellite communications, navigation and positioning services, and earth observation.

The satellite segment represents a significant portion of the overall market, alongside growing areas such as space infrastructure, software platforms, and emerging commercial applications. Increased participation from private companies continues to play a central role in the expansion of the sector.

Leadership Team

Etienne Moshevich, Chief Executive Officer, has a background in capital markets and private investing and has focused on evaluating, financing, and advising early-stage and growth companies across multiple sectors. His role includes portfolio strategy, capital allocation, and investor relations, with a focus on aligning management teams and shareholders toward long-term outcomes.

Desmond Balakrishnan, Executive Director, is a partner at McMillan LLP and an experienced capital markets and securities lawyer. He has advised clients across multiple industries and has experience in private equity investments, public offerings, mergers and acquisitions, and listed company advisory.

Brian Shin, Chief Financial Officer, specializes in financial reporting, corporate finance, auditing, corporate strategy, and risk management. He provides accounting and consulting services to both public and private companies and has served as CFO for multiple organizations in Canada.

For more information, visit the company’s website at https://planetventuresinc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

• Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies.
• Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behçet’s disease.
• SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators.

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behçet’s disease, reinforcing both the promise of the therapy and the company’s broader development strategy.

Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Orphan drug designation in the European Union (“EU”) is specifically intended to encourage the development of treatments for rare diseases, which are defined as conditions affecting no more than five in 10,000 people in the EU. These designations provide important incentives, including protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval, all of which are designed to support the advancement of therapies that might otherwise face significant development barriers.

Such recognition also signals that a therapy addresses a condition with a high unmet medical need and demonstrates the potential to provide meaningful clinical benefit. The European Medicines Agency notes that orphan designation is granted when a product is intended to diagnose, prevent or treat a life-threatening or chronically debilitating condition and where existing treatment options are limited or inadequate. For companies such as Soligenix, this type of validation can help accelerate development, attract investment and enhance visibility within the global healthcare community.

The condition targeted by SGX945, Behçet’s disease, is a rare and chronic inflammatory disorder characterized by inflammation of blood vessels throughout the body. Behçet’s disease can cause recurring symptoms such as painful oral and genital ulcers, skin lesions and inflammation affecting multiple organ systems, and it may lead to serious complications depending on the organs involved. The disease is often relapsing in nature and can significantly impact quality of life, underscoring the need for effective and well-tolerated treatment options.

Against this backdrop, Soligenix announced that the European Commission, acting on a positive recommendation from the European Medicines Agency’s Committee for Orphan Medicinal Products, granted orphan drug designation to SGX945 (dusquetide) for the treatment of Behçet’s disease. This designation represents a key milestone in the development of the therapy and aligns with the company’s focus on addressing rare and difficult-to-treat conditions.

SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. These molecules are designed to modulate the body’s immune response, promoting an anti-inflammatory and tissue-healing profile while enhancing the body’s ability to respond to infection. This mechanism represents a novel therapeutic approach for inflammatory and immune-mediated diseases, including Behçet’s Disease, where dysregulated immune activity plays a central role.

Orphan drug designation in the European Union provides a range of development and commercial advantages. These include eligibility for protocol assistance from the European Medicines Agency, access to centralized marketing authorization procedures and a 10-year period of market exclusivity upon approval, all of which are intended to support the successful development and commercialization of therapies for rare conditions.

In addition to its regulatory benefits, the designation reinforces the clinical rationale for SGX945. The therapy has demonstrated encouraging results in earlier studies, including improvements in oral ulcer outcomes among patients with Behçet’s disease and a favorable tolerability profile. These findings support continued development and suggest that the therapy may offer a meaningful alternative to existing treatment approaches.

The importance of SGX945 extends beyond a single indication. As part of Soligenix’s broader pipeline, the therapy reflects a platform-based approach that seeks to leverage scientific expertise across multiple programs targeting rare inflammatory and immune-related conditions. This strategy enables the company to pursue a range of therapeutic opportunities while maintaining a focused development framework.

The European Commission’s decision to grant orphan drug designation to SGX945 represents a meaningful step forward in that effort. By providing both regulatory support and commercial incentives, the designation helps position the therapy for continued advancement while highlighting its potential to address a significant unmet medical need. For patients living with Behçet’s Disease, where treatment options remain limited, such progress offers the possibility of improved outcomes and a better quality of life.

As Soligenix continues to advance its clinical programs, milestones such as this underscore the importance of collaboration between biotechnology innovators and global regulatory authorities. Together, these efforts play a critical role in bringing new therapies to patients with rare and challenging conditions, while reinforcing the value of scientific innovation in addressing unmet medical needs.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types
• First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity
• Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high

Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug regimens targeting different biological pathways are delivering results that single agents cannot.

Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is advancing a first-in-class compound designed to fit directly into that model. Rather than developing a standalone therapy, the company is focused on enhancing the effectiveness of existing treatments, specifically chemotherapy and immunotherapy, across a broader range of patients.

The Case for Combination Oncology

The shift toward combination-based treatment reflects a fundamental biological reality. Cancer cells are highly adaptive. Therapies that target a single pathway often lose effectiveness as tumors evolve alternative survival mechanisms.

The industry response has been to combine therapies that act through different mechanisms simultaneously. This approach is gaining traction as clinical data continues to show improved response rates and durability when targeted therapies are paired with immunotherapy or traditional chemotherapy.

The pattern is consistent: treatments that both damage cancer cells directly and activate the immune system tend to outperform either strategy alone. Lixte’s development strategy is built around that premise.

How LB-100 Fits the Model

LB-100 is a small molecule inhibitor of protein phosphatase 2A (“PP2A”), an enzyme involved in regulating key cellular functions, including DNA repair. By inhibiting PP2A, the compound disrupts the ability of cancer cells to recover from treatment-induced damage, increasing their susceptibility to chemotherapy and radiation.

At the same time, LB-100 has demonstrated immune-related activity. It promotes cytokine production, increases T-cell proliferation, and enhances the generation of neoantigens, helping the immune system better recognize and attack tumor cells.

This dual mechanism positions LB-100 as a complementary agent within combination regimens, particularly alongside immune checkpoint inhibitors such as PD-1 therapies.

Supporting the biological rationale, external research has shown that tumors with PP2A-related mutations may respond more favorably to immunotherapy, reinforcing the potential role of PP2A inhibition in enhancing immune response.

Clinical Development Across High-Need Indications

Lixte is advancing LB-100 across multiple clinical programs focused on solid tumors with limited treatment options.

In ovarian clear cell carcinoma, the compound is being evaluated in combination with a PD-1 inhibitor in a Phase 1b/2 study, with patient enrollment ongoing. Additional trials are exploring LB-100 in metastatic microsatellite-stable colorectal cancer, a setting where traditional immunotherapy has historically shown limited effectiveness.

The company has also completed Phase 1b enrollment in a study combining LB-100 with chemotherapy in advanced soft tissue sarcoma, with data analysis underway. This represents a potential near-term catalyst as the first meaningful readout from its combination strategy in that indication.

Preclinical research, supported by more than 25 published studies, has demonstrated anti-cancer activity across multiple tumor types, while early-stage clinical trials have established a favorable safety profile without significant increases in toxicity when used alongside standard treatments.

Addressing the Limits of Current Therapies

The rationale for a treatment enhancer like LB-100 is rooted in the limitations of existing therapies. Chemotherapy and immunotherapy both face challenges, including resistance, inconsistent response rates, and toxicity constraints that limit dosing.

A compound capable of increasing tumor sensitivity while also improving immune system engagement addresses those challenges directly. Rather than replacing established therapies, the goal is to improve how effectively they work.

This approach also aligns with growing focus on the tumor microenvironment, where immune activation is increasingly viewed as a critical factor in long-term outcomes.

Positioned Within an Evolving Treatment Landscape

As oncology continues to move toward personalized, multi-drug treatment strategies, the role of complementary therapies is expanding. Companies developing agents that enhance existing treatments, rather than competing with them, are becoming an important part of that ecosystem.

Lixte’s focus on PP2A inhibition, supported by ongoing clinical development and a defined patent portfolio, reflects that positioning.

The company’s long-term opportunity is tied to the success of combination oncology itself. If multi-drug regimens continue to define the next generation of cancer treatment, therapies designed to amplify existing standards of care may play a meaningful role in improving patient outcomes.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.

• Central bank gold buying has been unfolding against an international scenario that continues to favor safe-haven assets.
• Lahontan is working to build value through continued drilling, metallurgical work and project advancement.
• The company is showing a steady stream of updates this year, including drilling and key financing.

Gold’s appeal rarely rests on a single catalyst, and the current environment is no exception. Rising geopolitical tension, stubborn inflation risk, elevated sovereign debt and continued official-sector buying are all feeding the case for a renewed gold cycle, a backdrop that helps explain why Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) is drawing attention as it advances four gold and silver properties in Nevada’s Walker Lane, including its flagship Santa Fe Mine project

One reason the gold story still has momentum is that central banks have not meaningfully stepped away from the market. The World Gold Council reports that net central-bank demand reached 863 tonnes in 2025, far above the 2010–2021 annual average of 473 tonnes, and its broader 2025 Gold Demand Trends report notes that total gold demand topped 5,000 tonnes for the first time. That matters because it shows official buyers remained active even as prices reached record highs, reinforcing the view that gold is being treated not simply as a trade but as a strategic reserve asset.

The motivations behind that buying are also becoming clearer. In its 2025 Central Bank Gold Reserves Survey, the World Gold Council said central banks continued to rank economic and geopolitical factors highly in reserve-management decisions, with respondents citing inflation concerns, geopolitical instability, gold’s performance during crises and its diversification benefits. The same survey found that 76% of respondents believe gold will represent a higher share of total reserves five years from now, while 73% expect the U.S. dollar’s share of reserves to be lower. More recently, the council reported that central banks bought a net 27 tonnes in February 2026 and highlighted a growing number of African central banks turning to gold as a strategic diversification tool.

That official buying has been unfolding against an international scenario that continues to favor safe-haven assets. The IMF’s April 2026 World Economic Outlook says the global economy is now facing a major test from war in the Middle East and projects slower growth with somewhat higher headline inflation in 2026. In a related IMF blog post, the fund said that, whether the conflict is short or prolonged, the likely channels point toward higher prices and slower growth.

That mix of geopolitical instability and inflation risk matters because it revives two of gold’s oldest use cases at once: wealth preservation and insurance. The IMF’s press briefing on the April 2026 outlook said higher commodity prices are a classic negative supply shock that can raise costs, disrupt supply chains and erode purchasing power. Meanwhile, the IMF has also emphasized that debt burdens remain historically elevated, projecting global public debt would rise above 100% of GDP by 2029. A Finance & Development article reported that global public debt climbed to 93.9% of GDP in 2025 and is on track to breach 100% by 2028. When markets are asked to absorb war risk, inflation risk and debt risk at the same time, gold tends to stay part of the conversation

That is the macro setting in which Lahontan, a Canadian mine development and mineral exploration company with four top-tier properties in Nevada, is working to build value through continued drilling, metallurgical work and project advancement. The company’s Santa Fe project is a past-producing heap-leach operation with a sizeable current resource base. A National Instrument 43-101 compliant indicated resource of 1.539 million ounces gold equivalent and an inferred resource of 411,000 ounces gold equivalent, all pit constrained. Lahontan also says Santa Fe produced 356,000 ounces of gold and 784,000 ounces of silver between 1988 and 1995 through open-pit heap-leach mining.

Recent company activity shows the story is moving forward. Lahontan’s investor page shows a steady stream of 2026 updates, including metallurgical work, drilling and financing. The company also reported that it had mobilized a second drill rig to Santa Fe to augment ongoing drilling, with Executive Chair, President and CEO Kimberly Ann stating, “Since the company’s inception, Lahontan drilling has focused on resource definition and expansion to support our goal of resuming gold and silver production and mining operations at Santa Fe.” In February, the company also reported 36.6 meters grading 3.11 g/t gold equivalent from surface at West Santa Fe, including 10.7 meters grading 5.75 g/t gold equivalent, results that support shallow oxide mineralization with heap-leach potential.

The company has also been working to improve the technical case around recoveries and funding. Lahontan’s investor materials note an April 13, 2026, update reports cyanide recoveries of 81% for gold and 60% for silver at West Santa Fe, while the company also closed the final tranche of a private placement for aggregate proceeds of $13.6 million earlier this month. Earlier this year, Lahontan selected RESPEC and Kappes Cassiday to update the Santa Fe mineral resource estimate and PEA, a step that could prove meaningful in a stronger gold-price environment.

While there is no guarantee of success in the gold development space, Lahontan’s broader setup is hard to ignore. Central banks are still buying, governments are still diversifying reserves, war is still feeding safe-haven demand, and inflation and debt remain difficult to dismiss. For companies able to advance credible Nevada gold projects in that scenario, the market may be more willing to pay attention. Lahontan is focused on making that case with drilling, updated studies, metallurgical data and capital raises that keep Santa Fe and its surrounding properties moving ahead.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at ibn.fm/LGCXF

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF)and may include paid advertising.

• Canadian near-term precious metal producer ESGold is advancing toward the May start of a drill program expected to further define priority targets on its 20,618-hectare Montauban Gold-Silver Project in Quebec
• The company is simultaneously working to construct a fully permitted mill on site and expand the scope of its exploration
• ESGold is employing a low CapEx strategy that includes funding from a private placement initiative and an agreement with Ocean Partners UK Ltd. that provides a credit facility and a dedicated buyer of gold and silver produced from its planned tailings cleanup operation
• Despite market fluctuations, gold has effectively doubled in value since January 2025 and is expected to remain at near-record levels in the coming months, benefiting companies positioned to provide supply for continued demand

Clean process near-term gold and silver production company ESGold (CSE: ESAU) (OTCQB: ESAUF) is completing preparations for anticipated drilling operations in May at its Montauban Gold-Silver Project in Quebec while simultaneously progressing toward mill construction and an expanded exploration footprint. 

“We are fully funded to execute on this plan, and our focus is on disciplined execution across both development and exploration as we move through what we believe will be a very important period for the company,” ESGold CEO Gordon Robb stated in a news release earlier this month (https://ibn.fm/07Mcq).

ESGold is employing a tailings-cleanup-to-cash-flow model to generate revenues that can then be reinvested in the company’s operations, paving the way for new exploration at the site. 

“We are fully permitted for a thousand-ton-per-day [mill] operation. We’re fully funded to build the thousand-ton-per-day facility and we will be generating revenue to fund further exploration and development of the past-producing Montauban asset,” Robb added during an interview at the March Swiss Mining Institute (“SMI”) conference in Switzerland with conference Chairman Carlos Vargas (https://ibn.fm/o0odT).

“We have material sitting on surface. … If we can extract that economic value while cleaning up these tailings, it puts us in a very enviable position to be generating cash flow,” he added. “We have equipment arriving onsite. That building is complete. … We’re looking to be cash-flowing by the year-end.”

ESGold inked a C$9 million binding term sheet with Ocean Partners UK Ltd. last year that provides a credit facility to the company, while Ocean Partners buys the gold and silver dore produced from Montauban tailings and crown pillar material. The company had access to the first C$3 million tranche in February, while the remaining C$6 million will be available in a second tranche approximately five months before Phase 2 production, which is currently expected to begin next March. 

The targeted drill program will test zones identified as high potential areas by ESGold’s expanded Ambient Noise Tomography (“ANT”) imaging as well as data from historical drilling and detailed structural interpretation. 

“This is a past-producing asset that was never properly explored,” Robb said in the SMI interview. “The deepest drill hole went down to about 200 meters at depth. It was never drilled to the north [or] the south. We wanted to get a better idea of what we’re looking at, so we did an ANT survey coupled with a VTEM (Versatile Time Domain Electromagnetic) survey and we put together a 3-D model. … What we saw was something a lot bigger than originally anticipated. We found structure down to 900 meters at depth to the strike that looked [at least] 2 kilometers at length. It really excited our geologists and gave us a lot of targets.”

The program aims to determine if the mineralized corridor continues across the broader land package and to further define the scale and structural framework of the Montauban system, which spans 417 mining claims and 20,618 contiguous hectares (about 50,948 acres) across the Montauban and Chavigny townships west of Quebec City (https://ibn.fm/c2bvN).

“[The mill construction, ANT survey and drill program] are foundational steps, and they are all advancing at the same time. What is particularly exciting is how these initiatives come together. We are moving toward production while, in parallel, expanding our understanding of what we believe could be a much larger system,” Robb stated in the news release. 

Gold has enjoyed a massive surge in spot value since the beginning of the current U.S. administration, and while recent market fluctuations have brought gold back from its record peak in March the precious metal continues to enjoy a price level nearly double where it was in January 2025, creating optimism for gold sector producers positioned to provide supply for demand.

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Soligenix reports clinical update centered on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin.
• The interim update highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting.
• In addition, the company reported positive results from a study evaluating HyBryte(TM) against Valchlor(R), an existing treatment option for cutaneous T-cell lymphoma.

Advancing clinical research while generating positive data is a critical combination in biotechnology, particularly when addressing diseases with limited treatment options. Soligenix (NASDAQ: SNGX) is demonstrating that momentum as it provides  both an encouraging clinical update from its phase 3 FLASH2 study and positive comparative clinical results for its HyBryte therapy, reinforcing the company’s focus on developing innovative treatments for serious conditions.

The research highlighted in these announcements centers on cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin. According to the National Cancer Institute, CTCL can cause persistent skin lesions, plaques and tumors, often leading to significant discomfort and reduced quality of life. The disease is typically chronic and may require long-term treatment, making the development of effective and well-tolerated therapies particularly important.

Treatment options for CTCL remain limited, especially in early-stage disease where therapies are often used off-label or associated with notable side effects. The American Cancer Society notes that treatments such as phototherapy, topical therapies and systemic approaches are commonly used to manage symptoms of CTCL, although their effectiveness can vary and may not provide durable responses for all patients. In addition, some of these therapies carry risks with prolonged use, including skin irritation, damage and an increased risk of secondary skin cancers, underscoring the need for safer and more targeted treatment options.

The burden of the disease extends beyond physical symptoms. Chronic skin involvement, visible lesions and recurring flares can have a meaningful impact on quality of life, affecting both physical comfort and emotional well-being. As a result, ongoing research into therapies that can provide sustained efficacy with improved tolerability is considered a priority within the oncology and dermatology communities.

Against this backdrop, Soligenix has reported progress across two recent developments involving HyBryte, its investigational photodynamic therapy for CTCL. The company is continuing its phase 3 FLASH2 clinical trial, with an interim analysis expected in the second quarter of 2026 and topline results anticipated in the second half of the year. This late-stage study is designed to further evaluate the safety and efficacy of HyBryte following earlier clinical success.

The clinical update also highlighted that the overall blinded aggregate response rate observed in patients who have completed treatment remains consistent with prior reporting at approximately 48%, compared to a 25% response rate used to design the study. This difference is significant because it suggests that the therapy may be performing above initial expectations; final conclusions will depend on the unblinded data and full study results.

In addition, Soligenix reported positive results from a comparative study evaluating HyBryte against Valchlor, an existing treatment option for CTCL. The study measured outcomes over a 12-week treatment period and focused on defined improvements in disease severity.

According to the reported data, 60% of patients treated with HyBryte achieved the defined level of treatment success, compared to 20% of patients treated with Valchlor. The average cumulative improvement in disease severity scores was 52.5% in the HyBryte group compared to 34.7% in the Valchlor group, indicating a potentially stronger treatment effect.

The safety profile observed in the study further differentiates the therapy. HyBryte was reported to be well tolerated among treated patients, while a portion of patients receiving Valchlor experienced treatment-related adverse events, including skin reactions such as dermatitis and sensitivity at the application site. These findings are important because tolerability is a key consideration in chronic conditions that require ongoing treatment.

HyBryte is based on a photodynamic therapy approach that combines a light-activated compound with controlled exposure to visible light. This mechanism allows for targeted treatment of affected skin areas while minimizing systemic exposure, which may contribute to its favorable safety profile.

Together, the Phase 3 clinical update and comparative study results provide a clearer picture of HyBryte’s potential role in the treatment landscape for CTCL. The combination of encouraging efficacy signals and a favorable tolerability profile suggests that the therapy could address some of the limitations associated with existing treatments, particularly if these findings are confirmed in larger studies.

As Soligenix continues to advance its clinical programs, the data emerging from these studies highlight the importance of sustained research and innovation in rare and challenging diseases. With additional clinical milestones expected in 2026, the company’s progress reflects both the complexity of drug development and the potential impact of new therapeutic approaches on patient care.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX